Last updated on September 2018

PIONEER III Trial to Assess Safety and Efficacy of the BuMA Supreme Drug Coated Coronary Stent in Patients With Coronary Disease

Brief description of study

The primary objective of this trial is to compare the safety and efficacy of the SINOMED BuMA Supreme biodegradable coronary stent in patients with up to 3 coronary lesions to either the XIENCE or Promus durable polymer coronary stents.

This prospective, global, multi-center, randomized 2:1, single blind study will enroll up to 1632 subjects at up to 130 investigational sites in North America, Japan, and Europe. Subjects will have clinical follow-up in-hospital and at 30 days, 6 months, 12 months, and 2, 3, 4, and 5 years.

Clinical Study Identifier: NCT03168776

Contact Investigators or Research Sites near you

Start Over

Julie Bollen

Jessa Hospital
Hasselt, Belgium
  Connect »

Peter Carlyle

Ziekenhuis Oost Limburg Genk
Genk, Belgium
  Connect »